Concurrent use of Sr-89 chloride with bone-modifying agent(denosumab, zoledronic acid) is safe and effective for breast cancer patients with painful bone metastases

Concurrent use of Sr-89 chloride with bone-modifying agent(denosumab, zoledronic acid) is safe and effective for breast cancer patients with painful bone metastases - Concurrent use of Sr-89 chloride with bone-modifying agent is safe and effective for breast cancer patients with painful bone metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014269

Enrollment

Registered

2014-06-19

Start date

2014-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

concurrent use of the Sr-89 with bone-modifying agent (denosumab or zoredronic acid)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.breast cancer diagnosed with histologic or cytologic examination. 2.painful bone metastases indicated by bone scintigraphy . 3.primary medication used for Sr-89. 4.painful or not controlled pain with analgesic. 5. WBC>3000/mm3, neutrophilic leukocyte >1500/mm3, plt>75000/3, Hb>9.0g/dl 6. serum Cr<1.2mg/dl or creatinine clearance>60ml/min 7. Performance Status 0-2

Exclusion criteria

Exclusion criteria: 1. a case indicated chemotherapy 2. a case that has other cancer 3. a case that has grave complication 4. a case that has grave bone marrow suppression 5. a case that has grave renal dysfunction 6. a case that has invasive dental treatment 7. a woman that is pregnant, breast-feed and may be pregnant

Design outcomes

Primary

Measure	Time frame
incidence rates of myelotoxicity and hypocalcemia after fourth time uses of bone-modifying agent after use of Sr-89.	—

Secondary

Measure	Time frame
efficacy assessment to evaluated numerical rating scale, analgesic drug dosages, time to SRE, BAP or ALP, tumor marker, bone scintigraphy	—

Countries

Japan

Contacts

Public ContactTomoko Uejima

St. Marianna University School of Medicine Breast and Endocrine Surgery

chicoco@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026